Tag: subcutaneous cancer drug
-
FDA Approves Rybrevant Faspro: A Faster, Simpler Option for Certain Lung Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved Rybrevant Faspro, a newer formulation of the cancer drug amivantamab, offering a more convenient way to treat certain people with advanced lung cancer. While the science behind the drug is complex, the impact on patients’ daily lives is easier to understand: shorter treatment visits, fewer clinic